CELL: COVID-19 Medium Antibodies predict the life and death of patients

Coronavirus Infection 2019 (COVID-19) is caused by infection with Severe Acute Respiratory Syndrome Coronary Virus 2 (SARS-CoV-2), and COVID-19 exhibits clinical symptoms of varying severity, from asymptomatic to life-threatening.
, the effects of this differentiation on the development of protective immune responses and the role of antibodies in disease progression are unclear.
while countries are currently developing treatment options for mild and severe COVID-19 cases, we have limited understanding of the impact of these research therapies on the SARS-CoV-2 immune response.
Recently, researchers examined antibody responses in 113 COVID-19 patients and found that severe cases leading to intumping or death showed increased signs of inflammation, decreased lymphocytes, inflammatory cytokines, and high levels of anti-RBD antibodies.
although the level of RBD IgG resistance is generally related to the mesoth, the quantitative display of the meso-effect price shows that the high efficiency price is an indicator of the predicted survival rate.
In addition to the meso-wild SARS-CoV-2, patient serums can also mediat the recently occurring SARS-CoV-2 mutant D614G, suggesting that antibodies provide cross-protection against both strains of the virus to avoid host re-infection.
, however, SARS-CoV-2 serums generally lack cross-mediated for highly ionovirus WIV1-CoV, which has not yet crossed the species barrier.
results highlight the importance of neutralized body fluids for disease progression and the need for broad protective interventions to prevent future coronavirus pandemics.
。